STEREOCHEMISTRY AND ITS ROLE IN DRUG DESIGN
AbstractWhen designing small molecules to interact with the targets, one should consider stereo selectivity. As considerations for exploring structure space evolve, chirality is increasingly important. Binding affinity for a chiral drug can differ for diastereomers and between enantiomers. For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochemical information in structure libraries leading to a “coin toss” as to whether or not the “ideal” chiral structure is present. Creating every stereoisomer for each chiral compound in a structure library leads to an exponential increase in the number of structures resulting in potentially unmanageable file sizes and screening times. Therefore, only key chiral structures, enantiomeric pairs based on relative stereochemistry need be included, and lead to a compromise between exploration of chemical space and maintaining manageable libraries. In clinical environments, enantiomers of chiral drugs can have reduced, no, or even deleterious effects. This underscores the need to avoid mixtures of compounds and focus on chiral synthesis. Governmental regulations emphasizing the need to monitor chirality in drug development have increased. The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compounds. These guidelines require that absolute stereochemistry be known for compounds with chiral centers and that this information should be established early in drug development in order that the analysis can be considered valid. From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance
Article Information
4
4644-4659
781
6289
English
IJPSR
K. Singh *, P. Shakya, A. Kumar, S. Alok, M. Kamal and S. P. Singh
Faculty of pharmacy, Integral University, Dasauli, Lucknow, Uttar Pradesh. India
kuldeepsani2020@gmail.com
19 April 2014
10 June 2014
15 July 2014
10.13040/IJPSR.0975-8232.5(11).4644-59
01 November 2014